Advertisement
Advertisement
U.S. markets close in 5 hours 25 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Kuke Music Holding Limited (KUKE)

NYSE - Nasdaq Real Time Price. Currency in USD
0.5400+0.0350 (+6.93%)
As of 09:32AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close0.5050
Open0.5600
Bid0.0000 x 800
Ask0.0000 x 1000
Day's Range0.5400 - 0.5400
52 Week Range0.3300 - 4.2500
Volume613
Avg. Volume10,257
Market Cap15.966M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-0.2900
Earnings DateJan 20, 2023 - Jan 21, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KUKE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kuke Music Holding Limited
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Rating
    Fair Value
    Economic Moat
    4 months agoMorningstar
View more
  • PR Newswire

    Kuke Music Launches Advanced Digital Teaching System in Collaboration with People's Music Publishing House

    Kuke Music Holding Limited ("Kuke" or the "Company") (NYSE: KUKE), a leading classical music service platform in China with approximately 3 million audio and video music tracks, announced the launch of an advanced digital music teaching system in collaboration with People's Music Publishing House. The highly innovative Music Museum is a comprehensive digital music teaching system, including licensed Chinese music and classical music learning content. The product will be sold through offline chan

  • PR Newswire

    Kuke's Ground Breaking Talent Program Reaches Record Enrollment Level

    Kuke Music Holding Limited ("Kuke" or the "Company") (NYSE: KUKE), a leading classical music service platform in China with approximately 3 million audio and video music tracks, announced the Company's ground breaking Youth Artist Development Program, which is focused on competition, discovery and development of young artistic talent, has reached a record enrollment level. Nearly 8,500 students have already successfully enrolled in the Company's 2022 program, up 200% year-on-year and representin

  • PR Newswire

    Kuke Music Supports Prominent Beijing Forum for Performing Arts

    Kuke Music Holding Limited ("Kuke" or the "Company") (NYSE: KUKE), a leading classical music service platform in China, announced the Company's attendance at the recently held China National Center for the Performing Arts ("China NCPA" ) hosted Beijing Forum for Performing Arts 2022. The theme of this year's global forum was "Revitalizing the Performing Arts: Tradition and Innovation". Participants from over 30 countries and more than 100 art institutions participated both online and in-person i

Advertisement
Advertisement